Cytotoxicity of iron oxide nanoparticles made from the thermal decomposition of organometallics and aqueous phase transfer with Pluronic F127

Contrast Media and Molecular Imaging

Volumn 5, Issue 5, 2010, Pages 286-293

  Gonzales, Marcela ^a   Mitsumori, Lee M ^b   Kushleika, John V ^c   Rosenfeld, Michael E ^c   Krishnan, Kannan M ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

colorimetric assay; cytotoxicity; molecular imaging; MRI; nanoparticles; Pluronics; superparamagnetic agents

Indexed keywords

LACTATE DEHYDROGENASE; ORGANIC SOLVENT; ORGANOMETALLIC COMPOUND; POLOXAMER; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; CELL ASSAY; CELL CULTURE; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DECOMPOSITION; DRUG COATING; DRUG CYTOTOXICITY; DRUG SOLUBILITY; DRUG SYNTHESIS; MONOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CELL SURVIVAL; COLORIMETRY; FERRIC COMPOUNDS; MAGNETIC RESONANCE IMAGING; MAGNETICS; MICE; NANOPARTICLES; POLOXAMER;

EID: 78349249461     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.391     Document Type: Article

References (31)

1. Bowen CV, Zhang X, Saab G, Gareau PJ, Rutt BK,. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med 2002; 48 (1): 52 - 61.
2. Wood ML, Hardy PA,. Proton relaxation enhancement. J Magn Reson Imag 1993; 3 (1): 149 - 156.
3. Fahlvik AK, Klaveness J, Stark DD,. Iron oxides as MR imaging contrast agents. J Magn Reson Imag 1993; 3 (1): 187 - 194.
4. Roca AG, Morales MP, Serna CJ,. Synthesis of monodispersed magnetite particles from different organometallic precursors. IEEE Trans Magn 2006; 42 (10): 3025 - 3029.
5. Tartaj P, del Puerto Morales M, Veintemillas-Verdaguer S, Gonzalez-Carreno T, Serna CJ,. The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys 2003; 36 (13): 182 - 197.
6. Rheinlaender T, Koetitz R, Weitschies W, Semmler W,. Magnetic fractionation of magnetic fluids. J Magn Magn Mater 2000; 219 (2): 219 - 228.
7. Rheinlaender T, Roessner D, Weitschies W, Semmler W,. Comparison of size-selective techniques for the fractionation of magnetic fluids. J Magn Magn Mater 2000; 214 (3): 269 - 275.
8. Romanus E, Koettig T, Glockl G, Prass S, Schmidl F, Heinrich J, Gopinadhan M, Berkov DV, Helm CA, Weitschies W, Weber P, Seidel P,. Energy barrier distributions of maghemite nanoparticles. Nanotechnology 2007; 18 (11): 1 - 8.
9. Gonzales M, Krishnan KM,. Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia. J Magn Magn Mater 2005; 293 (1): 265 - 270.
10. Hyeon T, Lee SS, Park J, Chung Y, Na HB,. Synthesis of highly crystalline and monodisperse maghemite nanocrystallites without a size-selection process. J Am Chem Soc 2001; 123 (51): 12798 - 12801.
11. Bao Y, Pakhomov AB, Krishnan KM,. A general approach to synthesis of nanoparticles with controlled morphologies and magnetic properties. J Appl Phys 2005; 97 (10): 10.
12. Gonzales M, Krishnan KM,. Phase transfer of highly monodisperse iron oxide nanocrystals with Pluronic F127 for biomedical applications. J Magn Magn Mater 2007; 311: 59 - 62.
13. Kabanov A, Zhu J, Alakhov V,. Pluronic block copolymers for gene delivery. Adv Genet 2005; 53PA: 231 - 261.
14. Goppert TM, Muller RH,. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm 2005; 60 (3): 361 - 372.
15. Goppert TM, Muller RH,. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 2005; 302 (1-2): 172 - 186.
16. Muldoon LL, Sandor M, Pinkston KE, Neuwelt EA,. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery 2005; 57 (4): 785 - 796 discussion 785-796.
17. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J,. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989; 152 (1): 167 - 173.
18. Bacon BR, Stark DD, Park CH, Saini S, Groman EV, Hahn PF, Compton CC, Ferrucci JT, Jr., Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration. J Lab Clin Med 1987; 110 (2): 164 - 171.
19. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, Kim S, Cho EJ, Yoon HG, Suh JS, Cheon J,. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007; 13 (1): 95 - 99.
20. Soenen SJ, De Cuyper M,. Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cationic magnetoliposomes. Contrast Media Mol Imag 2009; 4 (5): 207 - 219.
21. Monteiro-Riviere NA, Inman AO, Zhang LW,. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicology Appl Pharmacol 2009; 234 (2): 222 - 235.
22. Diaz B, Sanchez-Espinel C, Arruebo M, Faro J, de Miguel E, Magadan S, Yague C, Fernandez-Pacheco R, Ibarra MR, Santamaria J, Gonzalez-Fernandez A,. Assessing methods for blood cell cytotoxic responses to inorganic nanoparticles and nanoparticle aggregates. Small (Weinheim an der Bergstrasse, Germany) 2008; 4 (11): 2025 - 2034.
23. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG,. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 2007; 95 (2): 300 - 312.
24. Stern S, Potter T,. NCL Method GTA-2 V.1 HEP G2 Hepatocarcinoma Cytotoxicity Assay, 2006. [17 January 2007].
25. William WY, Chang E, Sayes CM, Drezek R, Colvin VL,. Aqueous dispersion of monodisperse magnetic iron oxide nanocrystals through phase transfer. Nanotechnology 2006; 17 (17): 4483 - 4487.
26. Ahmad S, Ahmad A, Schneider KB, White CW,. Cholesterol interferes with the MTT assay in human epithelial-like (A549) and endothelial (HLMVE and HCAE) cells. Int J Toxicol 2006; 25 (1): 17 - 23.
27. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB,. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47 (4): 936 - 942. (Pubitemid 17027905)
28. Decker T, Lohmann-Matthes ML,. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Meth 1988; 115 (1): 61 - 69.
29. Denizot F, Lang R,. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 1986; 89 (2): 271 - 277.
30. Legrand C, Bour JM, Jacob C, Capiaumont J, Martial A, Marc A, Wudtke M, Kretzmer G, Demangel C, Duval D, et al. Lactate dehydrogenase (LDH) activity of the cultured eukaryotic cells as marker of the number of dead cells in the medium [corrected]. J Biotechnol 1992; 25 (3): 231 - 243.
31. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65 (1-2): 55 - 63.